Selected research
Industry Research
Multi-target MET TKIs Industry Research Report 2026
Market perspective
The global Multi-target MET TKIs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Multi-target MET TKIs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Multi-target MET TKIs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Multi-target MET TKIs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Multi-target MET TKIs include BDR Pharma, Beacon Pharmaceuticals, Drug International, Elemento Pharma, Everest Pharmaceuticals, Exelixis, Genvio Pharma, MSN Labs and Zydus, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Multi-target MET TKIs market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Multi-target MET TKIs Market by Company
BDR Pharma
Beacon Pharmaceuticals
Drug International
Elemento Pharma
Everest Pharmaceuticals
Exelixis
Genvio Pharma
MSN Labs
Zydus
Pfizer
Stada Arzneimittel
Teva
万邦医药
Cipla
Multi-target MET TKIs Segment by Type
Crizotinib
cabozantinib
Other
Multi-target MET TKIs Segment by Application
Medullary Thyroid Cancer
Non-small Cell Lung Cancer
Other
Multi-target MET TKIs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Multi-target MET TKIs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Multi-target MET TKIs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Multi-target MET TKIs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Multi-target MET TKIs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Multi-target MET TKIs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Multi-target MET TKIs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Crizotinib
- cabozantinib
- Other
Applications
- Medullary Thyroid Cancer
- Non-small Cell Lung Cancer
- Other
Companies covered
- BDR Pharma
- Beacon Pharmaceuticals
- Drug International
- Elemento Pharma
- Everest Pharmaceuticals
- Exelixis
- Genvio Pharma
- MSN Labs
- Zydus
- Pfizer
- Stada Arzneimittel
- Teva
- 万邦医药
- Cipla
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Multi-target MET TKIs Market Size (2021-2032)
- 2.2.2 Global Multi-target MET TKIs Sales (2021-2032)
- 2.2.3 Global Multi-target MET TKIs Market Average Price (2021-2032)
- 2.3 Multi-target MET TKIs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Crizotinib
- 2.3.3 cabozantinib
- 2.3.4 Other
- 2.4 Multi-target MET TKIs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Medullary Thyroid Cancer
- 2.4.3 Non-small Cell Lung Cancer
- 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Multi-target MET TKIs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Multi-target MET TKIs Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Multi-target MET TKIs Revenue of Manufacturers (2021-2026)
- 3.4 Global Multi-target MET TKIs Average Price by Manufacturers (2021-2026)
- 3.5 Global Multi-target MET TKIs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Multi-target MET TKIs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Multi-target MET TKIs, Product Type & Application
- 3.8 Global Manufacturers of Multi-target MET TKIs, Established Date
- 3.9 Global Multi-target MET TKIs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 BDR Pharma
- 4.1.1 BDR Pharma Company Information
- 4.1.2 BDR Pharma Business Overview
- 4.1.3 BDR Pharma Multi-target MET TKIs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 BDR Pharma Multi-target MET TKIs Product Portfolio
- 4.1.5 BDR Pharma Recent Developments
- 4.2 Beacon Pharmaceuticals
- 4.2.1 Beacon Pharmaceuticals Company Information
- 4.2.2 Beacon Pharmaceuticals Business Overview
- 4.2.3 Beacon Pharmaceuticals Multi-target MET TKIs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Beacon Pharmaceuticals Multi-target MET TKIs Product Portfolio
- 4.2.5 Beacon Pharmaceuticals Recent Developments
- 4.3 Drug International
- 4.3.1 Drug International Company Information
- 4.3.2 Drug International Business Overview
- 4.3.3 Drug International Multi-target MET TKIs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Drug International Multi-target MET TKIs Product Portfolio
- 4.3.5 Drug International Recent Developments
- 4.4 Elemento Pharma
- 4.4.1 Elemento Pharma Company Information
- 4.4.2 Elemento Pharma Business Overview
- 4.4.3 Elemento Pharma Multi-target MET TKIs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Elemento Pharma Multi-target MET TKIs Product Portfolio
- 4.4.5 Elemento Pharma Recent Developments
- 4.5 Everest Pharmaceuticals
- 4.5.1 Everest Pharmaceuticals Company Information
- 4.5.2 Everest Pharmaceuticals Business Overview
- 4.5.3 Everest Pharmaceuticals Multi-target MET TKIs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Everest Pharmaceuticals Multi-target MET TKIs Product Portfolio
- 4.5.5 Everest Pharmaceuticals Recent Developments
- 4.6 Exelixis
- 4.6.1 Exelixis Company Information
- 4.6.2 Exelixis Business Overview
- 4.6.3 Exelixis Multi-target MET TKIs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Exelixis Multi-target MET TKIs Product Portfolio
- 4.6.5 Exelixis Recent Developments
- 4.7 Genvio Pharma
- 4.7.1 Genvio Pharma Company Information
- 4.7.2 Genvio Pharma Business Overview
- 4.7.3 Genvio Pharma Multi-target MET TKIs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Genvio Pharma Multi-target MET TKIs Product Portfolio
- 4.7.5 Genvio Pharma Recent Developments
- 4.8 MSN Labs
- 4.8.1 MSN Labs Company Information
- 4.8.2 MSN Labs Business Overview
- 4.8.3 MSN Labs Multi-target MET TKIs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 MSN Labs Multi-target MET TKIs Product Portfolio
- 4.8.5 MSN Labs Recent Developments
- 4.9 Zydus
- 4.9.1 Zydus Company Information
- 4.9.2 Zydus Business Overview
- 4.9.3 Zydus Multi-target MET TKIs Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Zydus Multi-target MET TKIs Product Portfolio
- 4.9.5 Zydus Recent Developments
- 4.10 Pfizer
- 4.10.1 Pfizer Company Information
- 4.10.2 Pfizer Business Overview
- 4.10.3 Pfizer Multi-target MET TKIs Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Pfizer Multi-target MET TKIs Product Portfolio
- 4.10.5 Pfizer Recent Developments
- 4.11 Stada Arzneimittel
- 4.11.1 Stada Arzneimittel Company Information
- 4.11.2 Stada Arzneimittel Business Overview
- 4.11.3 Stada Arzneimittel Multi-target MET TKIs Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Stada Arzneimittel Multi-target MET TKIs Product Portfolio
- 4.11.5 Stada Arzneimittel Recent Developments
- 4.12 Teva
- 4.12.1 Teva Company Information
- 4.12.2 Teva Business Overview
- 4.12.3 Teva Multi-target MET TKIs Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Teva Multi-target MET TKIs Product Portfolio
- 4.12.5 Teva Recent Developments
- 4.13 万邦医药
- 4.13.1 万邦医药 Company Information
- 4.13.2 万邦医药 Business Overview
- 4.13.3 万邦医药 Multi-target MET TKIs Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 万邦医药 Multi-target MET TKIs Product Portfolio
- 4.13.5 万邦医药 Recent Developments
- 4.14 Cipla
- 4.14.1 Cipla Company Information
- 4.14.2 Cipla Business Overview
- 4.14.3 Cipla Multi-target MET TKIs Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Cipla Multi-target MET TKIs Product Portfolio
- 4.14.5 Cipla Recent Developments
5 Global Multi-target MET TKIs Market Scenario by Region
- 5.1 Global Multi-target MET TKIs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Multi-target MET TKIs Sales by Region: 2021-2032
- 5.2.1 Global Multi-target MET TKIs Sales by Region: 2021-2026
- 5.2.2 Global Multi-target MET TKIs Sales by Region: 2027-2032
- 5.3 Global Multi-target MET TKIs Revenue by Region: 2021-2032
- 5.3.1 Global Multi-target MET TKIs Revenue by Region: 2021-2026
- 5.3.2 Global Multi-target MET TKIs Revenue by Region: 2027-2032
- 5.4 North America Multi-target MET TKIs Market Facts & Figures by Country
- 5.4.1 North America Multi-target MET TKIs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Multi-target MET TKIs Sales by Country (2021-2032)
- 5.4.3 North America Multi-target MET TKIs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Multi-target MET TKIs Market Facts & Figures by Country
- 5.5.1 Europe Multi-target MET TKIs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Multi-target MET TKIs Sales by Country (2021-2032)
- 5.5.3 Europe Multi-target MET TKIs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Multi-target MET TKIs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Multi-target MET TKIs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Multi-target MET TKIs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Multi-target MET TKIs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Multi-target MET TKIs Market Facts & Figures by Country
- 5.7.1 South America Multi-target MET TKIs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Multi-target MET TKIs Sales by Country (2021-2032)
- 5.7.3 South America Multi-target MET TKIs Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.7.7 Colombia
- 5.8 Middle East and Africa Multi-target MET TKIs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Multi-target MET TKIs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Multi-target MET TKIs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Multi-target MET TKIs Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Multi-target MET TKIs Sales by Type (2021-2032)
- 6.1.1 Global Multi-target MET TKIs Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Multi-target MET TKIs Sales Market Share by Type (2021-2032)
- 6.2 Global Multi-target MET TKIs Revenue by Type (2021-2032)
- 6.2.1 Global Multi-target MET TKIs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Multi-target MET TKIs Revenue Market Share by Type (2021-2032)
- 6.3 Global Multi-target MET TKIs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Multi-target MET TKIs Sales by Application (2021-2032)
- 7.1.1 Global Multi-target MET TKIs Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Multi-target MET TKIs Sales Market Share by Application (2021-2032)
- 7.2 Global Multi-target MET TKIs Revenue by Application (2021-2032)
- 7.2.1 Global Multi-target MET TKIs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Multi-target MET TKIs Revenue Market Share by Application (2021-2032)
- 7.3 Global Multi-target MET TKIs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Multi-target MET TKIs Value Chain Analysis
- 8.1.1 Multi-target MET TKIs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Multi-target MET TKIs Production Mode & Process
- 8.2 Multi-target MET TKIs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Multi-target MET TKIs Distributors
- 8.2.3 Multi-target MET TKIs Customers
9 Global Multi-target MET TKIs Analyzing Market Dynamics
- 9.1 Multi-target MET TKIs Industry Trends
- 9.2 Multi-target MET TKIs Industry Drivers
- 9.3 Multi-target MET TKIs Industry Opportunities and Challenges
- 9.4 Multi-target MET TKIs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst